Yuyu Pharma, Inc. (000227.KS)
KRW 9750.0
(-0.41%)
KRW 9750.0
(-0.41%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 39.4 Billion KRW | 0.33% |
| 2022 | 39.27 Billion KRW | 0.28% |
| 2021 | 39.16 Billion KRW | 96.32% |
| 2020 | 19.94 Billion KRW | -25.95% |
| 2019 | 26.94 Billion KRW | -0.99% |
| 2018 | 27.21 Billion KRW | 40.12% |
| 2017 | 19.41 Billion KRW | 14.91% |
| 2016 | 16.9 Billion KRW | -3.12% |
| 2015 | 17.44 Billion KRW | 246.83% |
| 2014 | 5.02 Billion KRW | -35.95% |
| 2013 | 7.85 Billion KRW | 613.87% |
| 2012 | 1.1 Billion KRW | -81.82% |
| 2011 | 6.05 Billion KRW | -34.59% |
| 2010 | 9.25 Billion KRW | -32.73% |
| 2009 | 13.75 Billion KRW | -48.6% |
| 2008 | 26.75 Billion KRW | -16.42% |
| 2007 | 32 Billion KRW | -22.37% |
| 2006 | 41.22 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 36.63 Billion KRW | -7.04% |
| 2024 Q2 | 35.65 Billion KRW | -2.68% |
| 2023 FY | 39.4 Billion KRW | 0.33% |
| 2023 Q3 | 43.26 Billion KRW | -5.55% |
| 2023 Q2 | 45.8 Billion KRW | 11.68% |
| 2023 Q4 | 39.4 Billion KRW | -8.92% |
| 2023 Q1 | 41.01 Billion KRW | 4.43% |
| 2022 Q4 | 39.27 Billion KRW | -0.57% |
| 2022 FY | 39.27 Billion KRW | 0.28% |
| 2022 Q3 | 39.5 Billion KRW | -1.86% |
| 2022 Q2 | 40.24 Billion KRW | 0.96% |
| 2022 Q1 | 39.86 Billion KRW | 1.78% |
| 2021 FY | 39.16 Billion KRW | 96.32% |
| 2021 Q2 | 39.11 Billion KRW | 69.98% |
| 2021 Q3 | 37.03 Billion KRW | -5.32% |
| 2021 Q4 | 39.16 Billion KRW | 5.77% |
| 2021 Q1 | 23.01 Billion KRW | 15.34% |
| 2020 Q2 | 40.61 Billion KRW | 34.68% |
| 2020 FY | 19.94 Billion KRW | -25.95% |
| 2020 Q3 | 30.21 Billion KRW | -25.61% |
| 2020 Q1 | 30.15 Billion KRW | 11.94% |
| 2020 Q4 | 19.94 Billion KRW | -33.98% |
| 2019 Q4 | 26.94 Billion KRW | 11.09% |
| 2019 Q3 | 24.25 Billion KRW | 8.62% |
| 2019 FY | 26.94 Billion KRW | -0.99% |
| 2019 Q1 | 24.56 Billion KRW | -9.71% |
| 2019 Q2 | 22.33 Billion KRW | -9.11% |
| 2018 Q2 | 37.57 Billion KRW | 67.91% |
| 2018 FY | 27.21 Billion KRW | 40.12% |
| 2018 Q4 | 27.21 Billion KRW | -23.85% |
| 2018 Q3 | 35.73 Billion KRW | -4.9% |
| 2018 Q1 | 22.37 Billion KRW | 0.0% |
| 2017 FY | 19.41 Billion KRW | 14.91% |
| 2017 Q1 | 16.9 Billion KRW | -2.54% |
| 2017 Q2 | 16.9 Billion KRW | 0.0% |
| 2017 Q3 | 18.07 Billion KRW | 6.92% |
| 2016 Q4 | 17.34 Billion KRW | -0.0% |
| 2016 Q3 | 17.34 Billion KRW | -0.37% |
| 2016 Q2 | 17.4 Billion KRW | -0.23% |
| 2016 Q1 | 17.44 Billion KRW | 12.95% |
| 2016 FY | 16.9 Billion KRW | -3.12% |
| 2015 Q1 | 5.02 Billion KRW | 262.81% |
| 2015 FY | 17.44 Billion KRW | 246.83% |
| 2015 Q4 | 15.44 Billion KRW | 30.95% |
| 2015 Q3 | 11.79 Billion KRW | -14.5% |
| 2015 Q2 | 13.79 Billion KRW | 174.26% |
| 2014 Q4 | 1.38 Billion KRW | -75.54% |
| 2014 Q3 | 5.66 Billion KRW | -28.96% |
| 2014 Q2 | 7.97 Billion KRW | 1.61% |
| 2014 Q1 | 7.85 Billion KRW | -0.02% |
| 2014 FY | 5.02 Billion KRW | -35.95% |
| 2013 Q3 | 4.98 Billion KRW | 30.04% |
| 2013 Q2 | 3.83 Billion KRW | 248.22% |
| 2013 FY | 7.85 Billion KRW | 613.87% |
| 2013 Q1 | 1.1 Billion KRW | 0.0% |
| 2013 Q4 | 7.85 Billion KRW | 57.68% |
| 2012 FY | 1.1 Billion KRW | -81.82% |
| 2011 Q4 | 5 Billion KRW | -20.0% |
| 2011 Q2 | 9.5 Billion KRW | 2.7% |
| 2011 Q3 | 6.25 Billion KRW | -34.21% |
| 2011 Q1 | 9.25 Billion KRW | -10.19% |
| 2011 FY | 6.05 Billion KRW | -34.59% |
| 2010 Q3 | 12.28 Billion KRW | -1.76% |
| 2010 Q2 | 12.5 Billion KRW | -9.09% |
| 2010 Q1 | 13.75 Billion KRW | -31.25% |
| 2010 Q4 | 10.3 Billion KRW | -16.13% |
| 2010 FY | 9.25 Billion KRW | -32.73% |
| 2009 Q4 | 20 Billion KRW | -5.88% |
| 2009 Q2 | 25.5 Billion KRW | -4.67% |
| 2009 Q3 | 21.25 Billion KRW | -16.67% |
| 2009 FY | 13.75 Billion KRW | -48.6% |
| 2009 Q1 | 26.75 Billion KRW | -23.1% |
| 2008 Q3 | 33.18 Billion KRW | 6.86% |
| 2008 Q1 | 32 Billion KRW | -9.69% |
| 2008 FY | 26.75 Billion KRW | -16.42% |
| 2008 Q4 | 34.78 Billion KRW | 4.82% |
| 2008 Q2 | 31.05 Billion KRW | -2.96% |
| 2007 Q2 | 38.56 Billion KRW | 0.0% |
| 2007 Q4 | 35.44 Billion KRW | -4.65% |
| 2007 Q3 | 37.17 Billion KRW | -3.61% |
| 2007 FY | 32 Billion KRW | -22.37% |
| 2006 FY | 41.22 Billion KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Dong-A Socio Holdings Co., Ltd. | 691.88 Billion KRW | 94.304% |
| Ildong Holdings Co., Ltd. | 382.06 Billion KRW | 89.686% |
| HANDOK Inc. | 300.01 Billion KRW | 86.865% |
| Kukje Pharma Co., Ltd. | 30.66 Billion KRW | -28.521% |
| Yuhan Corporation | 230.07 Billion KRW | 82.872% |
| Dong-A ST Co., Ltd. | 406.7 Billion KRW | 90.311% |
| SAMSUNG PHARM. Co., LTD. | 595.48 Million KRW | -6517.649% |
| Hanmi Pharm. Co., Ltd. | 572.86 Billion KRW | 93.121% |
| Hanall Biopharma Co.,Ltd | 1.29 Billion KRW | -2953.564% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | 53.726% |
| Dong Sung Bio Pharm.Co.,Ltd. | 43.27 Billion KRW | 8.933% |
| MYUNGMOON Pharm co.,Ltd | 90.48 Billion KRW | 56.448% |
| Hana Pharm Co., Ltd. | 26.53 Billion KRW | -48.521% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | 0.0% |
| Ilsung Pharmaceuticals Co., Ltd. | 238.12 Million KRW | -16448.867% |
| REYON Pharmaceutical Co., Ltd. | 225.05 Billion KRW | 82.49% |
| Aprogen pharmaceuticals,Inc. | 180.99 Billion KRW | 78.228% |
| JW Holdings Corporation | 554.58 Billion KRW | 92.894% |
| Ildong Pharmaceutical Co., Ltd. | 217.84 Billion KRW | 81.91% |
| Chong Kun Dang Pharmaceutical Corp. | 219.76 Billion KRW | 82.068% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 76.857% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | 14.613% |
| Hyundai Pharmaceutical Co., Ltd. | 39.2 Billion KRW | -0.516% |
| Samil Pharmaceutical Co.,Ltd | 175.87 Billion KRW | 77.594% |
| Jeil Pharmaceutical Co.,Ltd | 84.96 Billion KRW | 53.62% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | 0.0% |
| Kwang Dong Pharmaceutical Co., Ltd. | 235.64 Billion KRW | 83.277% |
| Daewoong pharmaceutical Co.,Ltd | 469.68 Billion KRW | 91.61% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 76.857% |
| Yuhan Corporation | 230.07 Billion KRW | 82.872% |
| Jeil Pharma Holdings Inc | 173.03 Billion KRW | 77.225% |
| Yungjin Pharm. Co., Ltd. | 66.88 Billion KRW | 41.08% |
| Suheung Co., Ltd. | 467.85 Billion KRW | 91.577% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 76.857% |
| Samjin Pharmaceuticals Co., Ltd. | 118.63 Billion KRW | 66.784% |
| Korea United Pharm Inc. | 40.33 Billion KRW | 2.31% |
| CKD Bio Corp. | 146.92 Billion KRW | 73.179% |
| Daewon Pharmaceutical Co., Ltd. | 146.04 Billion KRW | 73.018% |
| Dongwha Pharm.Co.,Ltd | 48.25 Billion KRW | 18.336% |
| Whan In Pharm Co.,Ltd. | 632.02 Million KRW | -6135.057% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | 14.613% |
| Chong Kun Dang Holdings Corp. | 468.03 Billion KRW | 91.58% |
| Boryung Corporation | 204.21 Billion KRW | 80.703% |
| Bukwang Pharmaceutical Co., Ltd. | 79.38 Billion KRW | 50.361% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | 53.726% |
| JW Lifescience Corporation | 46.31 Billion KRW | 14.911% |